These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 18303084)

  • 21. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.
    Wilhelm SM; Carter C; Tang L; Wilkie D; McNabola A; Rong H; Chen C; Zhang X; Vincent P; McHugh M; Cao Y; Shujath J; Gawlak S; Eveleigh D; Rowley B; Liu L; Adnane L; Lynch M; Auclair D; Taylor I; Gedrich R; Voznesensky A; Riedl B; Post LE; Bollag G; Trail PA
    Cancer Res; 2004 Oct; 64(19):7099-109. PubMed ID: 15466206
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and myeloid cell leukemia sequence 1 (Mcl-1).
    Fecteau JF; Bharati IS; O'Hayre M; Handel TM; Kipps TJ; Messmer D
    Mol Med; 2012 Feb; 18(1):19-28. PubMed ID: 21979753
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.
    Ambrosini G; Cheema HS; Seelman S; Teed A; Sambol EB; Singer S; Schwartz GK
    Mol Cancer Ther; 2008 Apr; 7(4):890-6. PubMed ID: 18413802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway.
    Peng CL; Guo W; Ji T; Ren T; Yang Y; Li DS; Qu HY; Li X; Tang S; Yan TQ; Tang XD
    Cancer Biol Ther; 2009 Sep; 8(18):1729-36. PubMed ID: 19633425
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reversal effects of low-dose imatinib compared with sunitinib on monocrotaline-induced pulmonary and right ventricular remodeling in rats.
    Leong ZP; Okida A; Higuchi M; Yamano Y; Hikasa Y
    Vascul Pharmacol; 2018 Jan; 100():41-50. PubMed ID: 29100963
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of MAPK and VEGFR by Sorafenib Controls the Progression of Endometriosis.
    Leconte M; Santulli P; Chouzenoux S; Marcellin L; Cerles O; Chapron C; Dousset B; Batteux F
    Reprod Sci; 2015 Sep; 22(9):1171-80. PubMed ID: 26169036
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats.
    Mejias M; Garcia-Pras E; Tiani C; Miquel R; Bosch J; Fernandez M
    Hepatology; 2009 Apr; 49(4):1245-56. PubMed ID: 19137587
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity.
    Cheng H; Kari G; Dicker AP; Rodeck U; Koch WJ; Force T
    Circ Res; 2011 Dec; 109(12):1401-9. PubMed ID: 21998323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models.
    Chang YS; Adnane J; Trail PA; Levy J; Henderson A; Xue D; Bortolon E; Ichetovkin M; Chen C; McNabola A; Wilkie D; Carter CA; Taylor IC; Lynch M; Wilhelm S
    Cancer Chemother Pharmacol; 2007 Apr; 59(5):561-74. PubMed ID: 17160391
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma.
    Gollob JA
    Clin Genitourin Cancer; 2005 Dec; 4(3):167-74. PubMed ID: 16425993
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MAPK-independent impairment of T-cell responses by the multikinase inhibitor sorafenib.
    Houben R; Voigt H; Noelke C; Hofmeister V; Becker JC; Schrama D
    Mol Cancer Ther; 2009 Feb; 8(2):433-40. PubMed ID: 19190114
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
    Ou DL; Shen YC; Liang JD; Liou JY; Yu SL; Fan HH; Wang DS; Lu YS; Hsu C; Cheng AL
    Clin Cancer Res; 2009 Sep; 15(18):5820-8. PubMed ID: 19737956
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2.
    Blechacz BR; Smoot RL; Bronk SF; Werneburg NW; Sirica AE; Gores GJ
    Hepatology; 2009 Dec; 50(6):1861-70. PubMed ID: 19821497
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.
    Augustine CK; Toshimitsu H; Jung SH; Zipfel PA; Yoo JS; Yoshimoto Y; Selim MA; Burchette J; Beasley GM; McMahon N; Padussis J; Pruitt SK; Ali-Osman F; Tyler DS
    Mol Cancer Ther; 2010 Jul; 9(7):2090-101. PubMed ID: 20571072
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endothelin-1 driven proliferation of pulmonary arterial smooth muscle cells is c-fos dependent.
    Biasin V; Chwalek K; Wilhelm J; Best J; Marsh LM; Ghanim B; Klepetko W; Fink L; Schermuly RT; Weissmann N; Olschewski A; Kwapiszewska G
    Int J Biochem Cell Biol; 2014 Sep; 54():137-48. PubMed ID: 25016214
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impaired Pulmonary Arterial Vasoconstriction and Nitric Oxide-Mediated Relaxation Underlie Severe Pulmonary Hypertension in the Sugen-Hypoxia Rat Model.
    Christou H; Hudalla H; Michael Z; Filatava EJ; Li J; Zhu M; Possomato-Vieira JS; Dias-Junior C; Kourembanas S; Khalil RA
    J Pharmacol Exp Ther; 2018 Feb; 364(2):258-274. PubMed ID: 29212831
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic Potential of Regorafenib-A Multikinase Inhibitor in Pulmonary Hypertension.
    Veeroju S; Kojonazarov B; Weiss A; Ghofrani HA; Weissmann N; Grimminger F; Seeger W; Novoyatleva T; Schermuly RT
    Int J Mol Sci; 2021 Feb; 22(3):. PubMed ID: 33540939
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.
    Wilhelm SM; Adnane L; Newell P; Villanueva A; Llovet JM; Lynch M
    Mol Cancer Ther; 2008 Oct; 7(10):3129-40. PubMed ID: 18852116
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib.
    Messmer D; Fecteau JF; O'Hayre M; Bharati IS; Handel TM; Kipps TJ
    Blood; 2011 Jan; 117(3):882-9. PubMed ID: 21079155
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells.
    Sugiyama H; Onuki K; Ishige K; Baba N; Ueda T; Matsuda S; Takeuchi K; Onodera M; Nakanuma Y; Yamato M; Yamamoto M; Hyodo I; Shoda J
    J Gastroenterol; 2011 Jun; 46(6):779-89. PubMed ID: 21331764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.